{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.3","upperLimit":"40.0","value":"21.9"},{"groupId":"OG001","lowerLimit":"5.1","upperLimit":"31.9","value":"15.2"},{"groupId":"OG002","lowerLimit":"23.7","upperLimit":"59.4","value":"40.6"},{"groupId":"OG003","lowerLimit":"4.7","upperLimit":"50.8","value":"21.4"},{"groupId":"OG004","lowerLimit":"32.5","upperLimit":"58.3","value":"45.2"},{"groupId":"OG005","lowerLimit":"25.0","upperLimit":"48.7","value":"36.2"},{"groupId":"OG006","lowerLimit":"26.0","upperLimit":"74.0","value":"50.0"},{"groupId":"OG007","lowerLimit":"9.9","upperLimit":"81.6","value":"42.9"}]}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.5","upperLimit":"29.0","value":"12.5"},{"groupId":"OG001","lowerLimit":"1.9","upperLimit":"24.3","value":"9.1"},{"groupId":"OG002","lowerLimit":"9.3","upperLimit":"40.0","value":"21.9"},{"groupId":"OG003","lowerLimit":"1.8","upperLimit":"42.8","value":"14.3"},{"groupId":"OG004","lowerLimit":"18.2","upperLimit":"41.9","value":"29.0"},{"groupId":"OG005","lowerLimit":"19.9","upperLimit":"42.7","value":"30.4"},{"groupId":"OG006","lowerLimit":"13.3","upperLimit":"59.0","value":"33.3"},{"groupId":"OG007","lowerLimit":"9.9","upperLimit":"81.6","value":"42.9"}]}],"title":"Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","upperLimit":"25.0","value":"9.4"},{"groupId":"OG001","lowerLimit":"0.1","upperLimit":"15.8","value":"3.0"},{"groupId":"OG002","lowerLimit":"7.2","upperLimit":"36.4","value":"18.8"},{"groupId":"OG003","lowerLimit":"0.2","upperLimit":"33.9","value":"7.1"},{"groupId":"OG004","lowerLimit":"15.5","upperLimit":"38.5","value":"25.8"},{"groupId":"OG005","lowerLimit":"18.7","upperLimit":"41.2","value":"29.0"},{"groupId":"OG006","lowerLimit":"9.7","upperLimit":"53.5","value":"27.8"},{"groupId":"OG007","lowerLimit":"0.4","upperLimit":"57.9","value":"14.3"}]}],"title":"Week 32"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","upperLimit":"25.0","value":"9.4"},{"groupId":"OG001","lowerLimit":"0.1","upperLimit":"15.8","value":"3.0"},{"groupId":"OG002","lowerLimit":"3.5","upperLimit":"29.0","value":"12.5"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"23.2","value":"0.0"},{"groupId":"OG004","lowerLimit":"14.2","upperLimit":"36.7","value":"24.2"},{"groupId":"OG005","lowerLimit":"13.9","upperLimit":"34.9","value":"23.2"},{"groupId":"OG006","lowerLimit":"1.4","upperLimit":"34.7","value":"11.1"},{"groupId":"OG007","lowerLimit":"0.4","upperLimit":"57.9","value":"14.3"}]}],"title":"Week 48"}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"62"},{"groupId":"OG005","value":"69"},{"groupId":"OG006","value":"18"},{"groupId":"OG007","value":"7"}],"units":"Participants"}],"description":"DCR was defined as the percentage of participants who achieved a confirmed response (CR or PR, as per RECIST v 1.1 criteria) or who have SD lasting at least 32 weeks from the start of treatment until disease progression or the start of subsequent anti-cancer therapy. CR was defined as disappearance of all target and non-target lesions. Any pathological lymph nodes must be \\<10 mm in the short axis. PR was defined as at least 30% decrease in sum of diameters of target lesions, taking as a reference, baseline sum of diameters. SD was defined neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with rhabdoid tumors (MRT, RTK, ATRT, and selected tumors with rhabdoid features, including SCCOHT, also known as MRTO) received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG000","title":"Rhabdoid Tumors: Cohort 1"},{"description":"Participants with relapsed or refractory synovial sarcoma with SS18-SSX rearrangement received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG001","title":"Synovial Sarcoma: Cohort 2"},{"description":"Participants with other INI-1-negative tumors or any solid tumor with EZH2 GOF mutation, including EMPNST, EMC, myoepithelial carcinoma, other INI-1-negative malignant tumors with sponsor approval, any solid tumor with EZH2 GOF mutation including but not limited to Ewing's sarcoma and melanoma received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG002","title":"Other INI1-negative: Cohort 3"},{"description":"Participants with RMC received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG003","title":"RMC: Cohort 4"},{"description":"Participants with ES received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG004","title":"ES: Cohort 5"},{"description":"Participants with ES undergoing optional tumour biopsy received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG005","title":"ES Paired Biopsy: Cohort 6"},{"description":"Participants with poorly differentiated chordoma (or other chordoma with sponsor approval) received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG006","title":"Chordoma: Cohort 7"},{"description":"Participants with ES received tazemetostat 1600 mg QD orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG007","title":"ES 1600 mg: Cohort 8"}],"paramType":"NUMBER","populationDescription":"ITT population included all participants who received at least 1 dose of tazemetostat.","reportingStatus":"POSTED","timeFrame":"At Weeks 12, 24, 32 and 48","title":"All Cohorts: Disease Control Rate (DCR) at Weeks 12, 24, 32 and 48","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}